Gate2Brain's Bridge Fundraising Round 2025

Gate2Brain opens a round of bridge financing aimed at Business Angels and Family Offices for its pediatric cancer program, with the aim of transforming the future of treatments

Barcelona, October 2024 – Gate2Brain, an innovative technological platform, has developed, as indicated by its motto “Medicines Beyond Barriers”, a technology capable of making drugs cross the blood-brain barrier and reach the brain more effectively. Given this key moment, Gate2Brain wants to highlight three fundamental axes of its project:

Orphan Drug Designation (ODD): G2B-002 has recently received orphan drug designation from the European Medicines Agency (EMA).
€1.5 M Financing Round: Gate2Brain launches a bridge financing round of €1.5 million in convertible notes to boost the clinical development of its product.
Impact on Pediatric Oncology: Gate2Brain’s technology has the potential to revolutionize the treatment of aggressive pediatric brain tumors, such as diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM), as a first indication. Its flagship product, G2B-002, has the potential to transform the treatment of this devastating cancer, delivering drugs to the brain with greater precision.

Our pediatric brain tumor research program, led by experts in pediatric biotechnology and neuro-oncology, has recently obtained orphan drug designation (ODD) for G2B-002 from the EMA. Although it has raised €0.6M in equity and €3.5M in non-dilutive financing, it is essential to have additional financial support to move from laboratory to patient. It is worth remembering that brain tumors are the leading cause of cancer-related deaths in children, with pGBM and DIPG accounting for 25% and 10% of all childhood brain tumors, respectively.

“We are moving towards clinical trials that could change the future of the treatment of pediatric brain tumors,” comments Meritxell Teixidó, CEO of Gate2Brain.

Business Angels and Family Offices seek both financial returns and social impact, and this is where our goals align: transforming lives through innovation. Gate2Brain opens this round of bridge financing of €1.5 M in convertible notes, with a minimum investment of €25,000, aimed at Business Angels and Family Offices, to accelerate regulatory processes, ensure preclinical production and prepare clinical trials in the Sant Joan de Déu Hospital, a world-renowned center in pediatric oncology. This investment offers investors the opportunity to generate financial returns while having a significant social impact for families seeking new therapeutic options.

About Gate2Brain

Gate2Brain is a technology platform, spin-off of IRB Barcelona, the University of Barcelona and the Hospital Sant Joan de Déu, founded in 2020. Gate2Brain uses its patented peptide-based technology to cross biological barriers, such as the blood-brain barrier (BBB). ), with the aim of improving the efficiency of drug transport in the brain and reducing side effects. The company has received support from institutions such as Fundación Botín, Banco Sabadell, the CDTI and the European Innovation Council. Gate2Brain has the vision of improving the quality of life of patients through technology that provides greater efficiency in drug transportation.